Overview

Detailed Summary

Dishman Carbogen Amcis Limited is a global CDMO specializing in complex active pharmaceutical ingredients (APIs) and high active ingredients, serving biotech and pharmaceutical markets.
The company is expanding its integrated CDMO capabilities with ongoing expansions at facilities in Switzerland, France, and India to accommodate rising customer demands.
Recent financial performance has shown improvement, despite certain deferrals in revenue due to supply chain delays, indicating robust operational resilience.
The company's strategy includes significant focus on oncology drugs, showcasing leadership in high-potency ingredients, supported by successful developments in ADC and Vitamin D analogues.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 2,854 Cr
Volatility: High Risk
P/E Ratio: 29.3
Industry P/E: 34.1
PEG Ratio: 0.3
P/B Ratio: 0.4
52W High: 321.15
52W Low: 129.00

Sales CAGR

1Y: 3.66%
3Y: 9.25%
5Y: -7.19%
10Y: 57.23%

Profit CAGR

1Y: 102.11%
3Y: —
5Y: —
10Y: —

ROE

TTM: 1.46%
3Y: -1.19%
5Y: -1.94%
10Y: -0.63%

ROCE

TTM: 2.66%
3Y: -0.25%
5Y: -0.90%
10Y: 0.47%

Technicals

‌

Forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
AARTIDRUGS		374.00	3,443 Cr	17.66	2.22	0.00	12.58	11.51	6.92
NOVARTIND		1311.30	3,288 Cr	35.29	4.02	0.00	11.39	15.94	9.52
DCAL		188.75	2,957 Cr	30.34	0.44	0.00	1.46	2.66	0.82
SOLARA		577.95	2,758 Cr	-372.13	2.20	0.00	-0.12	4.81	-0.32
MOREPENLAB		48.64	2,665 Cr	28.09	2.14	0.41	5.96	7.58	4.94
UNICHEMLAB		378.00	2,662 Cr	10.53	0.98	0.00	2.88	3.79	6.77
SAIPARENT		560.00	2,478 Cr	173.65	5.05	0.00	2.91	2.79	—
Median: 7 Co.	—	378.00	2,758 Cr	28.09	2.20	0.00	2.91	4.81	5.85

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	651	655	524	789	682	716	708	653	720	851
Expenses	610	592	495	642	542	564	567	504	607	688
Operating Profit	41	63	29	147	140	153	141	149	113	163
OPM %	6.31	9.57	5.53	18.65	20.54	21.32	19.87	22.81	15.71	19.14
Other Income	6.05	4.07	-4.01	3.69	7.67	-3.78	22	8.11	6.66	15
Interest	33	31	32	37	49	42	43	42	46	43
Depreciation	80	85	71	72	72	79	81	84	84	89
Profit Before Tax	-66	-49	-78	42	27	28	39	31	-10	46
Tax %	10.05	-42.11	-0.01	21.44	82.88	-55.56	39.46	-113.72	-24.23	52.87
Net Profit	-60	-70	-78	33	4.63	43	23	65	-13	22
EPS in Rs	-3.80	-4.46	-4.95	2.11	0.30	2.75	1.49	4.16	-0.83	1.39

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	1,714	1,695	2,059	2,044	1,912	2,141	2,413	2,616	2,712	2,896
Expenses	1,260	1,249	1,507	1,546	1,638	1,809	2,081	2,329	2,243	2,315
Operating Profit	453	445	552	498	274	331	332	287	469	581
OPM %	26.45	26.28	26.81	24.35	14.35	15.48	13.77	10.95	17.29	20.05
Other Income	25	46	54	44	16	29	-20	22	3.57	30
Interest	49	49	57	62	48	57	86	120	159	170
Depreciation	214	211	240	283	308	308	281	311	294	305
Profit Before Tax	216	231	309	197	-65	-4.25	-55	-122	19	136
Tax %	32.70	33.03	31.89	19.62	-153.93	523.76	45.41	-25.51	83.22	23.11
Net Profit	145	155	210	159	-165	18	-30	-153	3.24	104
EPS in Rs	8.91	9.84	13.45	10.03	-10.53	1.14	-1.89	-9.79	0.21	6.21
Dividend Payout %	0.00	0.00	1.53	0.00	0.00	0.00	0.00	0.00	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2013	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	16	0.00	32	32	31	31	31	31	31	31
Reserves	1,018	4,814	5,075	5,347	5,684	5,667	5,518	5,778	5,596	5,800
Borrowings	800	845	918	883	1,231	1,589	1,830	2,209	2,313	2,389
Other Liabilities	457	934	1,151	1,067	1,254	1,078	1,259	1,435	1,641	1,779
Total Liabilities	2,291	6,593	7,176	7,328	8,200	8,366	8,637	9,454	9,581	9,999
Fixed Assets	1,373	4,847	5,061	5,092	5,673	5,693	5,768	6,183	6,720	7,051
CWIP	97	133	151	175	234	486	780	1,043	646	467
Investments	25	44	201	172	196	177	329	254	106	102
Other Assets	796	1,569	1,764	1,889	2,097	2,010	1,761	1,973	2,109	2,380
Total Assets	2,291	6,593	7,176	7,328	8,200	8,366	8,637	9,454	9,581	9,999

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2013	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	137	303	226	282	585	513	355	266	384	375
Cash from Investing Activity	-90	-142	-297	-169	-442	-380	-619	-494	-230	-192
Cash from Financing Activity	-50	-137	78	-102	-98	-11	130	250	-22	-102
Net Cash Flow	-3.04	23	6.92	11	46	122	-133	22	132	81

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	59.32%	59.32%	59.32%	59.32%	59.32%	59.32%	59.32%	59.32%	59.32%	59.32%	59.32%	59.32%
FIIs	8.90%	8.80%	8.61%	8.70%	8.04%	8.17%	8.74%	9.49%	9.93%	8.07%	7.66%	7.45%
DIIs	3.14%	3.52%	3.69%	2.37%	1.47%	1.23%	1.42%	1.26%	1.27%	1.37%	1.27%	1.63%
Public	28.64%	28.36%	28.39%	29.61%	31.16%	31.28%	30.51%	29.93%	29.47%	31.23%	31.75%	31.60%
Total Shareholders	56,221	56,272	52,336	50,656	53,683	55,280	52,822	50,757	49,744	49,455	48,481	49,009

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q4 FY26

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Available on Pro Plan